Sofosbuvir improves renal safety in patients with chronic hep C

Sofosbuvir improves renal safety in patients with chronic hep C
(HealthDay)—Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up, according to a study published online May 7 in the Journal of Clinical Pharmacy and Therapeutics.

Thalia Medeiros, from the Universidade Federal Fluminense in Niterói, Brazil, and colleagues evaluated renal biomarkers among 94 chronic hepatitis C patients treated with sofosbuvir therapy. Urine samples were collected at the end of therapy, after 12 weeks sustained , and one year post-treatment.

The researchers found that 98.9 percent of patients reached sustained virological response. In patients with (GFR) ≥45 mL/min/1.73 m² there was significant improvement in renal biomarkers, as indicated by a progressive increase in mean GFR values until one year. There was no evidence of tubular dysfunction. There was no change in renal biomarkers among patients with baseline GFR <45 mL/min/1.73 m².

"In a 'real-life experience' of a Brazilian center, sofosbuvir therapy appears to guarantee renal safety for patients with C followed until one year after treatment," the authors write.


Explore further

HBV reactivation seen with DAA treatment of chronic hep C

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

Citation: Sofosbuvir improves renal safety in patients with chronic hep C (2018, May 11) retrieved 23 April 2019 from https://medicalxpress.com/news/2018-05-sofosbuvir-renal-safety-patients-chronic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more